Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Abingdon Health PLC ( (GB:ABDX) ) has provided an update.
Abingdon Health plc, a UK-headquartered med-tech CDMO focused on lateral flow diagnostics and regulatory services, serves an international client base from sites in York and Doncaster in England and Madison, Wisconsin in the USA. Its operations span product development, technology transfer, manufacturing, regulatory consulting and analytical testing for in vitro diagnostics and medical devices across multiple application areas.
The company will begin trading its ordinary shares on the US OTCQB Venture Market on 21 April 2026 under the ticker ABDXF, while retaining its primary listing on London’s AIM under ABDX. Management expects the dual trading presence to broaden access to US investors, deepen liquidity and complement its ongoing US facility expansion, giving customers greater manufacturing flexibility between the UK and US amid tariff and supply chain uncertainty.
Abingdon’s expanded Madison, Wisconsin site is intended to mirror its UK quality and manufacturing standards, allowing products developed by its US CDMO team to be manufactured domestically or in the UK as needed. The OTCQB listing is structured so that Abingdon, as a Foreign Private Issuer, faces no additional US reporting obligations beyond its existing home-market disclosures, limiting incremental costs while targeting the world’s largest lateral flow and med-tech market.
Spark’s Take on ABDX Stock
According to Spark, TipRanks’ AI Analyst, ABDX is a Neutral.
Abingdon Health PLC’s overall stock score is primarily influenced by its mixed financial performance, with strong revenue growth overshadowed by profitability and cash flow challenges. The technical analysis indicates a neutral trend, lacking strong momentum. The valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively result in a moderate overall score.
To see Spark’s full report on ABDX stock, click here.
More about Abingdon Health PLC
Abingdon Health plc is a med-tech contract service provider specialising in the development and manufacturing of rapid diagnostic lateral flow tests and related regulatory services. Through its CDMO operations and subsidiaries, it offers assay development, regulatory consultancy, and analytical testing to international customers across sectors including infectious disease, clinical and companion diagnostics, animal health and environmental testing. Founded in 2008 and headquartered in York, England, the group operates laboratories in Doncaster and commercial and laboratory facilities in Madison, Wisconsin, supporting customers seeking to bring in vitro diagnostic and medical device products to market in the USA, EU and UK.
Average Trading Volume: 195,344
Technical Sentiment Signal: Buy
Current Market Cap: £20.09M
For an in-depth examination of ABDX stock, go to TipRanks’ Overview page.